PUBLICATION

Global Business Reports

AUTHORS

Catherine Howe, Neha Premjee, Emma Johannes, Ben Cherrington

United States Biopharmaceuticals 2018

May 31, 2018

The United States has long been recognized as the innovation capital of the world for life sciences, well supported through a favorable IP framework and garnering attention from overseas as a high-value market. Under increasing scrutiny and pressure on drug pricing, companies are adapting drug development and market entry strategies – keeping the patient at the center of the process, trends towards precision medicine, more targeted treatments and better-defined patient populations are benefitting drug development timelines and costs through higher trial success rates. As companies’ strategies shift, the U.S. healthcare system itself will have to be adapted to absorb curative therapies entering the market. 

RELATED INTERVIEWS MORE INTERVIEWS

Tango Therapeutics is targeting unaddressed disease mechanisms in cancer to develop transformational new drugs for patients.
Founded in 2008, Eiger BioPharmaceuticals is a late-stage biopharmaceutical company focused on developing and commercializing targeted therapies for rare diseases.
Tosk, Inc. is a small molecule, oncology drug discovery and development company.
LabCental offers life science companies in Massachusetts at an early stage the facilities they need to develop

MACIG

Impala Terminals is expanding its services in sub Saharan Africa in tandem with the development of the mining industry and with the continents infrastructure developments.

SUBSCRIBE TO OUR NEWSLETTER